Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
IRTC
SellPremium GroweriRhythm Holdings, Inc. · Healthcare · United States · $4.0B · Avg Vol: $78M/d
COMPANY DESCRIPTION
iRhythm Holdings, Inc. develops and commercializes Zio, a wearable biosensor and AI-powered platform for the diagnosis of cardiac arrhythmias, providing extended continuous cardiac monitoring services. It is a market leader in ambulatory cardiac monitoring, leveraging proprietary, patient-friendly technology and a robust AI-driven analytics platform. The company benefits from strong clinical evidence and established reimbursement pathways.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 410.9M | 492.7M | 591.8M | 747.1M | 22.1% | 825.3M | 886.9M | 1.0B | 18.2% |
| EPS | -3.88 | -4.04 | -3.63 | -1.39 | — | -0.42 | — | — | — |
| Shares | 30.2M | 31.0M | 31.4M | 32.3M | +7.0% | 33.0M | — | — | — |
| Debt | 131.0M | 129.8M | 736.9M | 731.2M | 77.4% | 727.3M | — | — | — |
| Equity | 239.8M | 210.1M | 90.9M | 152.7M | -14.0% | — | — | — | — |
| Op CF | -23.0M | -50.1M | 3.4M | 80.9M | 2285.3% | 86.0M | — | — | — |
| Inv CF | -52.4M | -1.2M | -123.0M | -277.1M | — | — | — | — | — |
| Fin CF | 26.7M | 8.8M | 511.4M | 12.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IRTC are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IRTC | iRhythm Holdings, Inc.(you) | $4.0B | 34 | Sell |
| TMDX | TransMedics Group, Inc. | $3.1B | 28 | Sell |
| BFLY | Butterfly Network, Inc. | $2.2B | 41 | Hold |
| NEOG | Neogen Corporation | $2.5B | 46 | Hold |
| TNDM | Tandem Diabetes Care, Inc. | $1.5B | 31 | Sell |
| ESTA | Establishment Labs Holdings Inc. | $2.1B | 23 | Sell |
| AORT | Artivion, Inc. | $1.3B | 36 | Hold |
| ALMR | Alamar Biosciences, Inc. | $2.1B | 20 | Sell |
| ATEC | Alphatec Holdings, Inc. | $1.5B | 27 | Sell |
| BRKR | Bruker Corporation | $8.7B | 47 | Hold |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.1%